Report Description Table of Contents Methodology Segmentation Introduction And Strategic Context The Global Pharmaceutical Granulation Equipment Market, valued at USD 7.3 billion in 2024, is projected to expand to USD 11.2 billion by 2030, reflecting a 6.4% CAGR. This growth is primarily propelled by advancements in drug manufacturing, evolving pharmaceutical processing techniques, overall market growth, increasing tablet production demands, the integration of industrial automation, and innovations in granulation technology, according to Premier Market Insights. Central to this growth, granulation serves as a critical link between pharmaceutical formulation and scalable manufacturing. As drug developers increasingly focus on complex, high-potency molecules, the demand for specialized granulation systems, including fluid bed granulators, high-shear granulators, and twin-screw continuous systems, is on the rise. Driving this expansion, the core value of granulation lies in its ability to enhance process control. With regulatory bodies imposing stricter guidelines on product consistency and content uniformity, pharmaceutical companies now view granulation equipment as an essential quality assurance asset, rather than merely hardware. This perspective is particularly pronounced for formulations where precise granule size and structure are paramount for optimal solubility and bioavailability. Underpinning this trajectory, the expansion of generics manufacturing, notably in regions like India and Latin America, is stimulating demand for modular and cost-effective granulation lines. Simultaneously, contract development and manufacturing organizations (CDMOs) are scaling their operations by adopting high-throughput, continuous granulators to expedite time-to-market for their global clientele. Looking ahead, niche segments such as orphan drugs and pediatric formulations are also experiencing growth, where controlled granulation plays a vital role in meeting specific dosing requirements and taste-masking needs. Key factors influencing this market evolution include: The growing emphasis on personalized medicine necessitates adaptable batch sizes. The handling of potent compounds demands enclosed, low-dust operational systems. Regulatory authorities require real-time data monitoring for every production batch. Shaping this landscape, this convergence of demands is prompting equipment vendors to reconsider the fundamental role of granulation. Suppliers are now offering data-rich systems integrated with Process Analytical Technology (PAT), positioning the granulator as a vital component within the broader digital manufacturing network. Across the value chain, investment interest is focused on equipment suppliers possessing deep process expertise, attracting both OEMs and private equity firms. The primary stakeholders in this market comprise manufacturers, CDMOs, engineering consultants, and regulatory bodies, all united by the objective of achieving scalable, compliant, and efficient solid dose production. Comprehensive Market Snapshot The Global Pharmaceutical Granulation Equipment Market is projected to grow at a 6.4% CAGR, expanding from USD 7.3 billion in 2024 to USD 11.2 billion by 2030. APAC leads the global market with a 35.5% share, translating to USD 2.6 Billion in 2024, supported by large-scale generic drug production, expanding pharmaceutical infrastructure, and cost-efficient manufacturing ecosystems, and is expected to grow at a CAGR of 8.9% through 2030. USA represents a significant market with a 27.0% share, equivalent to USD 2.0 Billion in 2024, driven by advanced pharmaceutical processing capabilities and regulatory focus on quality manufacturing, progressing at a CAGR of 5.3%. Europe accounts for 26.0% share, reaching USD 1.9 Billion in 2024, supported by strong presence of established pharmaceutical companies and technological innovation, expanding at a CAGR of 4.2%. Regional Insights APAC accounted for the largest market share of 35.5% in 2024, driven by expanding pharmaceutical manufacturing hubs and cost-efficient production ecosystems. APAC is also expected to expand at the fastest CAGR of 8.9% during 2024–2030, supported by rising investments in continuous manufacturing and generics production. By Equipment Type Wet granulation equipment dominates the segment with a 44.0% share, valued at USD 3.2 Billion in 2024, owing to its versatility across a wide range of formulations and strong suitability for batch-based production environments. Continuous granulation systems emerge as the fastest-growing segment with a 2024 value of USD 1.7 Billion and are expected to expand at the highest CAGR during the forecast period, driven by increasing adoption of real-time quality monitoring and continuous manufacturing lines. Dry granulation equipment holds a considerable portion at approximately USD 2.4 Billion in 2024, supported by demand for solvent-free processing and suitability for moisture-sensitive and high-potency drugs. By Application Immediate-release formulations lead with a 38.0% share, amounting to USD 2.8 Billion in 2024, driven by high-volume production of standard oral dosage forms and widespread therapeutic usage. Sustained-release formulations represent a strong growth area with a 2024 value of USD 2.3 Billion and are expected to register a notable CAGR, supported by the need for prolonged drug efficacy and improved patient compliance. Effervescent applications contribute approximately USD 1.1 Billion in 2024, driven by demand for rapid dissolution and enhanced patient convenience. Specialty drug applications, including oncology and orphan drugs, also account for about USD 1.1 Billion, supported by increasing demand for controlled and small-batch production systems. By End User Pharmaceutical manufacturers hold the largest share at 45.0%, equivalent to USD 3.3 Billion in 2024, due to strong in-house production capabilities and large-scale tablet manufacturing operations. CDMOs are the fastest-growing segment with a 2024 value of USD 2.2 Billion and are projected to expand at a robust CAGR, driven by outsourcing trends and demand for flexible, multi-product manufacturing setups. Research institutes and pilot labs contribute around USD 1.1 Billion in 2024, supported by early-stage drug development activities and formulation testing needs. Nutraceutical manufacturers account for approximately USD 0.7 Billion, driven by increasing demand for dietary supplements and functional health products. Strategic Questions Driving the Global Pharmaceutical Granulation Equipment Market What equipment types, granulation technologies, and processing systems are included within the pharmaceutical granulation equipment market, and which adjacent processing technologies fall outside its scope? How does the pharmaceutical granulation equipment market differ structurally from related pharmaceutical processing equipment segments such as mixing, drying, coating, and compression systems? What is the current and projected market size of pharmaceutical granulation equipment globally, and how is value distributed across equipment types and manufacturing models? How is revenue distributed between wet granulation, dry granulation, and continuous granulation systems, and how is this mix expected to evolve over time? Which application areas (e.g., immediate-release, sustained-release, effervescent, specialty drugs) contribute the largest and fastest-growing demand for granulation equipment? Which equipment segments generate higher margins due to advanced automation, precision control, or regulatory compliance requirements rather than volume sales alone? How does demand vary between high-volume generic drug production and low-volume, high-value specialty or orphan drug manufacturing? How are batch processing and continuous manufacturing approaches evolving within pharmaceutical production workflows, and how does this shift impact equipment demand? What role do equipment lifecycle, maintenance cycles, and upgrade frequency play in recurring revenue and long-term market growth? How are pharmaceutical production volumes, drug pipeline expansion, and formulation complexity influencing demand for granulation equipment? What operational, regulatory, or validation challenges limit the adoption of advanced granulation systems in certain regions or facilities? How do capital investment constraints, cost pressures, and return on investment considerations affect purchasing decisions for granulation equipment? How strong is the innovation pipeline in granulation technology, and which advancements (e.g., real-time monitoring, AI integration, continuous processing) are expected to reshape the market? To what extent will new technologies expand overall equipment demand versus replace or upgrade existing installed systems? How are improvements in process efficiency, scalability, and automation enhancing performance and compliance across granulation platforms? How will equipment obsolescence and technological upgrades impact replacement cycles and competitive dynamics in the market? What role will modular systems and flexible manufacturing setups play in enabling multi-product and small-batch production environments? How are leading equipment manufacturers positioning their product portfolios and service offerings to capture growth across different granulation segments? Which geographic regions are expected to outperform global growth in the pharmaceutical granulation equipment market, and which factors are driving this expansion? How should manufacturers, suppliers, and investors prioritize specific technologies, applications, and regions to maximize long-term value creation in this market? Segment-Level Insights and Market Structure Pharmaceutical Granulation Equipment Market The pharmaceutical granulation equipment market is organized around core equipment technologies and operational deployment models, reflecting differences in formulation requirements, production scale, regulatory compliance, and manufacturing efficiency. Each segment contributes uniquely to total market value, competitive positioning, and long-term growth, influenced by evolving drug development trends, manufacturing modernization, and process optimization strategies. Equipment Type Insights Wet Granulation Equipment Wet granulation equipment continues to represent a core and widely adopted segment, particularly in conventional pharmaceutical manufacturing environments. Its importance lies in its ability to produce uniform, high-density granules suitable for a broad range of tablet formulations. This method is especially relevant for drugs that can tolerate moisture and heat, making it highly versatile across therapeutic categories. From a market standpoint, wet granulation remains a volume-driven segment, supported by its deep integration into legacy batch production systems and its compatibility with diverse excipient and API combinations. Its continued relevance is reinforced by reliability, scalability, and regulatory familiarity. Dry Granulation Equipment Dry granulation equipment occupies a strategically important niche, particularly in the production of moisture-sensitive and high-potency formulations. By eliminating the need for liquid binders, it supports simplified processing and reduced drying requirements, making it attractive in environments where efficiency and containment are critical. This segment is gaining traction in contract manufacturing and specialized drug production settings, where flexibility and contamination control are key priorities. Although smaller in volume compared to wet granulation, dry granulation offers operational advantages that align with modern pharmaceutical manufacturing needs. Continuous Granulation Systems Continuous granulation systems represent the most innovation-driven and rapidly evolving segment within the market. These systems enable real-time processing, consistent quality output, and seamless integration with continuous manufacturing lines. Their adoption is being driven by pharmaceutical companies seeking to enhance productivity, reduce batch variability, and align with regulatory initiatives encouraging advanced manufacturing technologies. While still emerging compared to traditional methods, continuous systems are increasingly shaping future-ready production environments, particularly in regions investing in digital transformation and smart manufacturing infrastructure. Application Insights Immediate-Release Formulations Immediate-release formulations form the largest application segment, driven by the high volume of standard oral dosage forms across therapeutic categories. Granulation plays a critical role in ensuring uniform particle size distribution and optimal compressibility, which are essential for rapid drug disintegration and absorption. This segment remains a stable and high-throughput contributor to equipment demand, supported by the continuous need for mass-market pharmaceutical products. Sustained-Release Formulations Sustained-release formulations are emerging as a strategically important growth segment, reflecting a shift toward therapies that offer prolonged drug action and improved patient adherence. These formulations require precise control over granule structure and coating characteristics, increasing reliance on advanced granulation technologies. As pharmaceutical companies focus on lifecycle management and differentiation of existing drugs, this segment is expected to drive demand for more sophisticated and controlled processing systems. Effervescent Applications Effervescent formulations represent a specialized application area, requiring granules with high porosity and controlled density to ensure rapid dissolution. Although smaller in scale, this segment benefits from growing consumer preference for easy-to-administer dosage forms, particularly in over-the-counter and nutraceutical products. Granulation equipment used here must support precision and consistency, making it a niche but technically demanding segment. Specialty and High-Potency Drug Applications Specialty drug applications, including oncology and orphan drugs, are contributing to a shift toward smaller batch sizes and high-containment processing. These applications demand flexible and highly controlled granulation systems capable of handling potent compounds safely. As the pharmaceutical pipeline increasingly includes targeted and personalized therapies, this segment is expected to influence equipment design toward modularity and adaptability. End User Insights Pharmaceutical Manufacturers Pharmaceutical manufacturers constitute the largest end-user segment, driven by extensive in-house production capabilities and the need for high-volume, standardized manufacturing processes. These organizations rely heavily on established granulation technologies to maintain consistent product quality and regulatory compliance. Their investment patterns often focus on capacity expansion, process optimization, and incremental technological upgrades. Contract Development and Manufacturing Organizations (CDMOs) CDMOs are becoming an increasingly influential segment, reflecting the broader industry shift toward outsourcing. These organizations require flexible, multi-purpose granulation systems capable of handling diverse formulations and varying batch sizes. Their role in supporting both large pharmaceutical companies and emerging biotech firms positions them as key adopters of advanced and modular equipment solutions, particularly in rapidly growing markets. Research Institutes and Pilot Facilities Research institutes and pilot-scale facilities represent a development-focused segment, where granulation equipment is used for formulation development, process optimization, and early-stage production. The demand here is centered on compact, adaptable systems that can replicate commercial-scale processes on a smaller scale. Although limited in volume, this segment plays a critical role in driving innovation and validating new manufacturing approaches. Nutraceutical Manufacturers Nutraceutical manufacturers utilize granulation equipment for the production of dietary supplements and functional health products, often at high volumes. This segment benefits from overlapping technology requirements with pharmaceutical production, while also demanding cost efficiency and scalability. As consumer health awareness increases, nutraceutical applications are expected to provide incremental growth opportunities for equipment suppliers. Segment Evolution Perspective The pharmaceutical granulation equipment market is undergoing a gradual transformation from conventional, batch-based systems toward more integrated and automated production environments. While established equipment types continue to anchor current demand, continuous technologies and flexible manufacturing solutions are redefining future growth pathways. At the same time, evolving application needs—ranging from high-volume generics to specialized therapies—are influencing how equipment is designed, deployed, and utilized. End users are increasingly prioritizing efficiency, scalability, and compliance, leading to a more dynamic and innovation-driven market structure over the forecast period. Market Segmentation And Forecast Scope The Global Pharmaceutical Granulation Equipment Market cuts across multiple technology layers and user segments — each aligned around optimizing particle size, density, and stability in solid dosage manufacturing. The segmentation isn’t just mechanical anymore; it reflects deeper shifts in formulation complexity, regulatory expectations, and production scale. By Equipment Type This market is most often segmented by granulation technology, with three dominant categories: Wet Granulation Equipment – Still the most widely used, wet granulation remains essential for heat- and moisture-tolerant APIs. High-shear mixers and fluid bed granulators dominate this space, especially in batch-based pharmaceutical environments. Dry Granulation Equipment – Gaining traction due to solvent-free processing, dry granulation (especially roller compaction) is preferred for moisture-sensitive drugs and high-potency APIs. It’s increasingly favored in CDMO settings where cross-contamination must be avoided and process speed matters. Continuous Granulation Systems – These systems are seeing rapid adoption in advanced manufacturing settings, especially where pharma companies are investing in real-time quality control. Twin-screw granulators and fully integrated continuous production lines are reshaping how innovators manage scale-up and validation. The fastest growth is expected in continuous systems — particularly in North America and Europe, where pharma plants are digitizing legacy infrastructure. By Application While granulation is a core step in tablet production, its applications are expanding: Immediate-release Formulations – Require rapid disintegration, often with larger surface area granules. Sustained-release Formulations – Involve matrix or coated granules, where uniformity in particle structure is essential. Effervescent Tablets & Sachets – Demand high porosity and precise density control. Oncology & Orphan Drug Batches – Often require mini-batch or contained granulation systems for safety and control. Formulations for sustained release are gaining more strategic focus, especially as drug developers seek to differentiate aging molecules. By End User Granulation equipment is used across various pharma production and development settings: Pharmaceutical Manufacturers – Large and mid-sized players managing internal tablet and capsule production. CDMOs – Contract firms offering full-service production, increasingly driving demand for flexible, scalable systems. Research Institutes & Pilot Labs – Require compact granulators for preclinical and early-phase work. Nutraceutical Manufacturers – Leveraging the same equipment to produce high-volume dietary supplements. CDMOs are becoming the primary demand generators in emerging markets, often building in modular granulation systems to serve multiple formulation types. By Region The geographic breakdown typically follows pharmaceutical production hubs: North America – Focused on innovation and compliance-driven upgrades. Europe – Strong adoption of continuous manufacturing principles. Asia Pacific – Largest volume contributor, driven by India and China’s dominance in generics. LAMEA – Catching up through government investments and expanding local production capabilities. Market Trends And Innovation Landscape Granulation equipment is evolving fast — not just in size or throughput, but in how it connects to broader pharmaceutical production goals. From automation to containment to hybrid systems, the Pharmaceutical Granulation Equipment Market is turning into a focal point of innovation in oral solid dosage manufacturing. Shift Toward Continuous Manufacturing Continuous granulation isn’t a future concept anymore — it’s already in deployment across North America and Western Europe. What’s changed is regulatory support. Agencies like the FDA and EMA now actively encourage continuous manufacturing through expedited review frameworks and pilot program collaboration. Several manufacturers are transitioning from traditional batch granulators to twin-screw continuous lines that offer in-line monitoring and 24/7 operability. This model supports faster scale-up, better process control, and fewer deviations — all critical when dealing with high-volume generics or time-sensitive oncology drugs. Integrated Process Analytical Technology (PAT) Process consistency has become non-negotiable. Vendors are embedding sensors and data acquisition tools directly into granulators, allowing operators to monitor: Granule moisture content Particle size distribution Compression profiles These real-time metrics are now being used to trigger adjustments mid-run — turning granulation from a static step into a dynamic feedback loop. In one example, a European CDMO deployed a high-shear granulator with real-time infrared moisture probes, cutting batch rejection rates by nearly 30%. Focus on High-Containment Granulation With the rise in high-potency active pharmaceutical ingredients (HPAPIs), containment is no longer optional. Granulation systems are now being built with: Fully enclosed designs CIP/SIP (clean-in-place / steam-in-place) features Negative pressure handling environments High-containment granulators are especially in demand in oncology production facilities, where operator safety and cross-contamination prevention are top priorities. Modular and Hybrid Systems Flexibility is everything in today’s pharma plants. Vendors are rolling out modular equipment that can switch between wet and dry granulation — or operate as part of both batch and continuous lines. This appeals to CDMOs handling multiple product types and batch sizes — especially when supporting early-stage clients who pivot formulations frequently. Modular systems also enable phased investments, which is a key factor in emerging markets and mid-sized firms balancing capital constraints. Smart Automation and AI Integration Granulation systems are joining the Industry 4.0 wave. New platforms now come with: AI-driven batch analytics Predictive maintenance algorithms Remote equipment diagnostics Some leading vendors have introduced granulators that learn optimal processing parameters across different API-excipient blends — reducing changeover times and batch trial cycles. Competitive Intelligence And Benchmarking The Pharmaceutical Granulation Equipment Market is concentrated around a handful of global players, but regional manufacturers are steadily gaining ground — especially in Asia and Eastern Europe. What separates market leaders today isn’t just mechanical design, but how well they integrate automation, compliance, and flexibility into their systems. Key Players GEA Group Based in Germany, GEA remains a dominant force in the granulation space. Its portfolio spans high-shear mixers, fluid bed processors, and continuous systems. What sets GEA apart is its push into Pharma 4.0 — offering granulators with built-in PAT and seamless connectivity to MES (Manufacturing Execution Systems). The company has a strong presence in both North America and EMEA, supported by dedicated pharma service teams. Glatt Glatt has carved out a strong position in fluid bed granulation. It is best known for its flexible modular systems and integrated containment options. Over the past few years, Glatt has deepened its footprint in Asia Pacific by partnering with regional integrators and launching more cost-sensitive models aimed at local manufacturers. Alexanderwerk Specializing in dry granulation and roller compaction, Alexanderwerk appeals to pharma companies working with moisture-sensitive APIs. Their focus is narrow, but the depth of engineering — especially in high-containment systems — has made them a go-to partner for oncology drug manufacturing and CDMOs producing high-potency compounds. Fette Compacting Though primarily known for tablet presses, Fette is increasingly blurring the lines between granulation and compression. Their integrated systems offer seamless handover from granule processing to final tablet formation, which appeals to high-output production lines aiming for zero waste and real-time quality control. L.B. Bohle L.B. Bohle has built a reputation around its continuous granulation lines. It’s one of the few companies offering full-line integration — from granulation to blending to compression — with real-time data visibility across the process. The company targets global innovators, especially in the U.S. and Western Europe, looking to modernize legacy production lines. Cadmach Machinery A key regional competitor based in India, Cadmach offers cost-effective batch granulators suited to the high-volume generic markets. The company’s systems are widely used by Indian pharma giants and are increasingly being exported to African and Middle Eastern markets as part of turnkey plant solutions. Strategic Positioning Global leaders like GEA , Glatt , and L.B. Bohle focus on high-end, digitally integrated solutions targeted at large-scale manufacturers and CDMOs in regulated markets. Meanwhile, firms like Cadmach and SaintyCo (China) are going after growth in emerging markets with affordable, customizable systems. Interestingly, regional firms are beginning to mimic top-tier functionality by adding basic PAT features and offering faster lead times — a move that’s putting price pressure on legacy vendors in mid-tier accounts. Regional Landscape And Adoption Outlook Adoption of granulation equipment isn’t evenly spread — it mirrors the maturity, regulation, and production models of each region. In the Global Pharmaceutical Granulation Equipment Market , some countries are racing toward digital transformation while others are still scaling up basic oral solid dose infrastructure. North America The U.S. leads in both volume and innovation. Most pharma majors and CDMOs in the region are moving toward continuous granulation, driven by strong FDA backing and a broader push toward Pharma 4.0 compliance. Continuous manufacturing is no longer experimental here — it’s operational in facilities making oncology, neurology, and metabolic drugs. Equipment buyers are demanding PAT integration, clean-in-place design, and full MES compatibility. Canada is also seeing moderate upgrades, mostly around flexible batch systems for regional generics. The North American buyer profile is shifting — not just big pharma, but CDMOs and mid-tier manufacturers upgrading for advanced formulations. Europe Western Europe, especially Germany, Switzerland, and the Netherlands, is a mature granulation market with high regulatory expectations. Equipment suppliers here are focused on reducing batch cycle time, supporting digital twins, and automating validation workflows. The EU’s evolving GMP frameworks have led to strong investments in data-integrated granulators. Demand is growing for systems that offer cleanroom optimization and rapid changeovers. Eastern Europe is catching up, with Poland and Hungary building granulation lines for local production and EU export. German-made granulators still dominate, but localized service hubs are emerging fast to meet tech support expectations. Asia Pacific This is the volume engine of the granulation market. India and China are the region’s heavyweights — not just in terms of pharmaceutical output but also as equipment manufacturers themselves. India’s generic drug giants are investing in both dry and wet granulation to expand exports to the U.S. and EU. China is balancing cost-sensitive batch production with pilot investments in continuous technology. Southeast Asia (especially Vietnam and Indonesia) is becoming a hub for nutraceuticals and regional generics. Asia Pacific’s growth is coming from both supply and demand: it makes the drugs, and increasingly, the machines too. Latin America, Middle East, and Africa (LAMEA) This region is still developing its pharmaceutical manufacturing base. Much of the demand here is driven by government-funded plants and public-private partnerships. Brazil and Mexico are the key adopters in Latin America, investing in fluid bed granulators to support national health initiatives. In the Middle East, countries like Saudi Arabia and the UAE are building pharma parks that include modern granulation lines. Sub-Saharan Africa remains early-stage but is receiving equipment through international funding channels. The opportunity here is long-term — as regulatory frameworks mature, local producers will require validated granulation equipment with basic automation and strong after-sales support. End-User Dynamics And Use Case End users in the Pharmaceutical Granulation Equipment Market aren't buying the same way they used to. The traditional buyer — a large in-house pharma plant — still exists, but they’re now joined by a wide spectrum of users: CDMOs, R&D centers , nutraceutical firms, and even academic labs. Each has very different expectations when it comes to system design, throughput, flexibility, and compliance. Key End-User Segments Pharmaceutical Manufacturers These are the largest consumers of granulation systems, typically purchasing high-throughput batch or continuous lines for internal solid dose production. Many are retrofitting old lines to meet newer GMP standards, particularly for combination therapies and complex generics. Their top priorities are scalability, PAT compatibility, and validation-ready systems. CDMOs (Contract Development and Manufacturing Organizations) This group is seeing the fastest growth. CDMOs require high-flexibility equipment — granulators that can handle frequent formulation changes and variable batch sizes. Because they often serve multiple clients, their focus is on cleanability, containment, and short changeover times. Continuous granulation systems are gaining popularity among mid- to large-scale CDMOs serving international markets. CDMOs now account for a significant share of first-time granulation system buyers — especially in India, Singapore, and the U.S. R&D Centers and Pilot-Scale Labs Used mainly for early-stage formulation and process development, these facilities prefer compact, modular systems with plug-and-play automation. Most demand dry granulation due to its minimal material requirements and faster cycle times. Their budgets are tighter, but so is their need for granule consistency, especially for scale-up predictability. Nutraceutical and Supplement Manufacturers While not strictly pharmaceutical, this group is growing rapidly and often uses the same equipment for high-volume vitamin and herbal product manufacturing. The requirements here focus more on cost-efficiency and throughput than stringent GMP features — though that's changing as some regions implement stricter nutraceutical oversight. A Real-World Use Case A CDMO based in Hyderabad, India, recently installed a hybrid granulation system — one that toggles between wet and dry modes — to serve a European client needing both effervescent and extended-release formulations. Prior to deployment, the CDMO relied on two separate units, creating logistical issues and regulatory documentation challenges. With the new system, they reduced validation cycle time by 40% and improved batch consistency across both product lines. This reflects a growing trend: the need for granulators that don’t just "work" but integrate seamlessly into multi-client, multi-regulatory workflows. Recent Developments + Opportunities & Restraints Recent Developments (Last 2 Years) A leading European equipment manufacturer launched a next-gen twin-screw continuous granulator with built-in AI calibration for real-time control of granule size and moisture. An Indian CDMO invested in a modular high-shear granulation line capable of multi-product runs, expanding its global GMP service capabilities. A global pharma firm deployed integrated PAT-enabled granulators across four of its facilities, as part of its broader Pharma 4.0 upgrade strategy. A China-based manufacturer released a compact roller compaction unit with full containment for oncology-grade APIs, targeting small and mid-sized production sites. One major North American supplier introduced remote diagnostics and digital twin support for its granulators, reducing downtime and improving maintenance planning across multiple customer locations. Opportunities Adoption of Continuous Manufacturing Rising preference for high-throughput, continuous granulation systems to reduce batch cycle times and enhance product uniformity. Emerging Market Expansion Increasing granulation equipment demand in Southeast Asia, Latin America, and Eastern Europe, where governments are backing local pharma manufacturing. Smart Automation & PAT Integration Growing emphasis on AI-driven process monitoring and inline quality assurance tools to comply with evolving global GMP norms. Restraints High Capital Investment Upfront cost of digital-ready granulation systems remains a barrier, especially for small and mid-sized manufacturers in cost-sensitive markets. Limited Skilled Workforce Shortage of technically trained staff to operate and maintain advanced granulation equipment, particularly in new pharma clusters and emerging regions. 7.1. Report Coverage Table Report Attribute Details Forecast Period 2024 – 2030 Market Size Value in 2024 USD 7.3 Billion Revenue Forecast in 2030 USD 11.2 Billion Overall Growth Rate CAGR of 6.4% (2024 – 2030) Base Year for Estimation 2024 Historical Data 2019 – 2023 Unit USD Million, CAGR (2024 – 2030) Segmentation By Equipment Type, By Application, By End User, By Geography By Equipment Type Wet Granulation, Dry Granulation, Continuous Granulation By Application Immediate-Release, Sustained-Release, Effervescent, Specialty Drugs By End User Pharmaceutical Manufacturers, CDMOs, Research Labs, Nutraceutical Firms By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, Germany, U.K., China, India, Japan, Brazil, GCC, South Africa Market Drivers • Rising need for high-containment processing in HPAPI production • Shift toward continuous manufacturing with PAT integration • Government support for localized pharmaceutical production Customization Option Available upon request Executive Summary Market Overview Market Attractiveness by Equipment Type, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Future Projections (2019–2030) Summary of Market Segmentation by Equipment Type, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Equipment Type, Application, and End User Investment Opportunities in the Pharmaceutical Granulation Equipment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Behavioral and Regulatory Factors Global Pharmaceutical Granulation Equipment Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Equipment Type Wet Granulation Dry Granulation Continuous Granulation Market Analysis by Application Immediate-Release Formulations Sustained-Release Formulations Effervescent Tablets & Sachets Specialty Drug Production Market Analysis by End User Pharmaceutical Manufacturers Contract Development and Manufacturing Organizations (CDMOs) Research and Academic Laboratories Nutraceutical and Supplement Manufacturers Market Analysis by Region North America Europe Asia-Pacific Latin America Middle East & Africa North America Pharmaceutical Granulation Equipment Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Equipment Type Market Analysis by Application Market Analysis by End User Country-Level Breakdown: United States Canada Europe Pharmaceutical Granulation Equipment Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Equipment Type Market Analysis by Application Market Analysis by End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Pharmaceutical Granulation Equipment Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Equipment Type Market Analysis by Application Market Analysis by End User Country-Level Breakdown: China India Japan South Korea Rest of Asia-Pacific Latin America Pharmaceutical Granulation Equipment Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Equipment Type Market Analysis by Application Market Analysis by End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Pharmaceutical Granulation Equipment Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Equipment Type Market Analysis by Application Market Analysis by End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Key Players and Competitive Analysis GEA Group – Leader in Continuous and Batch Systems Glatt – Specialist in Fluid Bed Granulation and Containment Alexanderwerk – Focused on Dry Granulation and Roller Compaction L.B. Bohle – Pioneer in Fully Integrated Lines Fette Compacting – Innovator in End-to-End Tablet Production Cadmach Machinery – High-Volume Batch Equipment for Generics Other Notable Companies Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Equipment Type, Application, End User, and Region (2024–2030) Regional Market Breakdown by Country and Segment (2024–2030) List of Figures Market Dynamics: Drivers, Restraints, and Opportunities Regional Market Snapshot Competitive Landscape and Market Share Distribution Growth Strategies Adopted by Key Players Comparative Market Share by Equipment Type and End User (2024 vs. 2030) Q1: How big is the pharmaceutical granulation equipment market? A1: The global pharmaceutical granulation equipment market was valued at USD 7.3 billion in 2024. Q2: What is the CAGR for the forecast period? A2: The market is projected to grow at a CAGR of 6.4% from 2024 to 2030. Q3: Who are the major players in this market? A3: Leading players include GEA Group, Glatt, Alexanderwerk, L.B. Bohle, Fette Compacting, and Cadmach Machinery. Q4: Which region dominates the market share? A4: North America leads the market due to early adoption of continuous manufacturing and strong regulatory support. Q5: What factors are driving this market? A5: Growth is driven by rising demand for high-containment processing, expansion of CDMO networks, and increased integration of PAT tools. .